![Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02](https://oncodaily.com/pub/uploads/2024/01/FDA.jpeg)
Apr 8, 2024, 16:01
Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02
Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:
“Trastuzumab Deruxtecan now FDA approved for pan-tumor with HER2 IHC3 and solid tumors who have received prior systemic treatment and have no alternative treatment options.
Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:
- Dose 5.4 mg/kg
- Common AE: fatigue, decreased counts and nausea. ILD can be fatal.”
Source: Rahul Gosain/LinkedIn
Aug 11, 2024, 05:12
Aug 11, 2024, 04:55
Aug 11, 2024, 04:37
Aug 11, 2024, 02:26